Literature DB >> 18500263

Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms.

Joshua Weaver1, Erinn Downs-Kelly, John R Goldblum, Sondra Turner, Sucheta Kulkarni, Raymond R Tubbs, Brian P Rubin, Marek Skacel.   

Abstract

Well-differentiated liposarcoma/atypical lipomatous tumor and dedifferentiated liposarcoma can be difficult to distinguish from benign lipomatous neoplasms and other high-grade sarcomas, respectively. Cytogenetics in these tumors has identified ring and giant chromosomes composed of 12q13-15 amplicons including the MDM2 gene. Identifying MDM2 amplification by fluorescence in situ hybridization may prove an adjunctive tool in the diagnosis of lipomatous neoplasms. Dual color fluorescence in situ hybridization employing a laboratory-developed BAC label probe cocktail specific for MDM2 (12q15) and a probe for the centromeric region of chromosome 12 (Abbott Molecular, DesPlaines, IL) was performed on formalin-fixed and paraffin-embedded tissue including whole sections from atypical lipomatous tumors (n=13), dedifferentiated liposarcomas (n=14), benign lipomatous tumors (n=30), and pleomorphic sarcoma, not otherwise specified (n=10), and a tissue microarray containing a variety of high-grade sarcomas (n=63). An MDM2/chromosome 12 ratio >or=2.0 was considered amplified, <2.0 nonamplified, and cases displaying >2 signals of both probes and an MDM2 ratio <2.0 polysomic for chromosome 12. Of the well-differentiated and dedifferentiated liposarcomas, 100% showed amplification of MDM2. Chromosome 12 polysomy was noted in 89% of spindle cell/pleomorphic lipomas, while all angiolipomas and lipomas were nonamplified and eusomic. MDM2 amplification was observed in 40% of pleomorphic sarcomas and a small subset of high-grade sarcomas (3/63). MDM2/chromosome 12 fluorescence in situ hybridization is a sensitive and specific tool (both 100%) in evaluating low-grade lipomatous neoplasms. The specificity decreases in high-grade sarcomas, as MDM2 amplification was observed in a small portion of pleomorphic sarcomas and high-grade sarcomas other than dedifferentiated liposarcomas. Importantly, none of the benign lipomatous lesions were MDM2 amplified and even cells in areas of well-differentiated liposarcomas with minimal cytologic atypia were amplified, making the probe a valuable tool in the diagnosis of even limited biopsy samples of well-differentiated lipomatous neoplasms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18500263     DOI: 10.1038/modpathol.2008.84

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  67 in total

Review 1.  [Molecular methods in the diagnosis of sarcoma].

Authors:  S Merkelbach-Bruse; E Wardelmann; H Künstlinger; R Büttner; H-U Schildhaus
Journal:  Pathologe       Date:  2011-02       Impact factor: 1.011

2.  Atypical spindle cell lipoma: a clinicopathologic, immunohistochemical, and molecular study emphasizing its relationship to classical spindle cell lipoma.

Authors:  David Creytens; Joost van Gorp; Suvi Savola; Liesbeth Ferdinande; Thomas Mentzel; Louis Libbrecht
Journal:  Virchows Arch       Date:  2014-07       Impact factor: 4.064

3.  Do Mesenchymal Stem Cells Derived From Atypical Lipomatous Tumors Have Greater Differentiation Potency Than Cells From Normal Adipose Tissues?

Authors:  Hiroyuki Inatani; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Akihiko Takeuchi; Shinji Miwa; Takashi Higuchi; Kensaku Abe; Yuta Taniguchi; Satoshi Yamada; Kiyofumi Asai; Takanobu Otsuka; Hiroyuki Tsuchiya
Journal:  Clin Orthop Relat Res       Date:  2017-02-02       Impact factor: 4.176

4.  SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.

Authors:  Shaomeng Wang; Wei Sun; Yujun Zhao; Donna McEachern; Isabelle Meaux; Cédric Barrière; Jeanne A Stuckey; Jennifer L Meagher; Longchuan Bai; Liu Liu; Cassandra Gianna Hoffman-Luca; Jianfeng Lu; Sanjeev Shangary; Shanghai Yu; Denzil Bernard; Angelo Aguilar; Odette Dos-Santos; Laurent Besret; Stéphane Guerif; Pascal Pannier; Dimitri Gorge-Bernat; Laurent Debussche
Journal:  Cancer Res       Date:  2014-08-21       Impact factor: 12.701

5.  Multiple sites of highly amplified DNA sequences detected by molecular cytogenetic analysis in HS-RMS-2, a new pleomorphic rhabdomyosarcoma cell line.

Authors:  Eiji Takaoka; Hiroshi Sonobe; Kunihiro Akimaru; Shuji Sakamoto; Taro Shuin; Masanori Daibata; Takahiro Taguchi; Akira Tominaga
Journal:  Am J Cancer Res       Date:  2012-02-19       Impact factor: 6.166

6.  Rare MDM2 amplification in a fat-predominant angiomyolipoma.

Authors:  Maria Del Carmen Rodriguez Pena; Jennifer Gordetsky; Patricia T Greipp; Shi Wei; Guido Martignoni; George J Netto; Shuko Harada; Carlos N Prieto Granada
Journal:  Virchows Arch       Date:  2020-05-15       Impact factor: 4.064

7.  Can HMGI-C be used as an aid with MDM2 and CDK4 to differentiate liposarcoma subtypes from their mimics?

Authors:  Hanan Alshenawy
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-26       Impact factor: 4.553

8.  Fine needle aspiration biopsy diagnosis of dedifferentiated liposarcoma: Cytomorphology and MDM2 amplification by FISH.

Authors:  Hatem Q Al-Maghraby; Walid E Khalbuss; Uma N M Rao; Kathleen Cieply; Sanja Dacic; Sara E Monaco
Journal:  Cytojournal       Date:  2010-04-06       Impact factor: 2.091

9.  Prognostic relevance of Fédération Nationale des Centres de Lutte Contre le Cancer grade and MDM2 amplification levels in dedifferentiated liposarcoma: a study of 50 cases.

Authors:  George Jour; Ashley Gullet; Mingdong Liu; Benjamin L Hoch
Journal:  Mod Pathol       Date:  2014-07-25       Impact factor: 7.842

Review 10.  Molecular pathology of sarcomas: concepts and clinical implications.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2009-09-29       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.